945 related articles for article (PubMed ID: 27012435)
1. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
2. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
[TBL] [Abstract][Full Text] [Related]
3. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
Jones JD; Sullivan MA; Vosburg SK; Manubay JM; Mogali S; Metz V; Comer SD
Addict Biol; 2015 Jul; 20(4):784-98. PubMed ID: 25060839
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
5. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
6. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
7. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
Comer SD; Collins ED
J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653
[TBL] [Abstract][Full Text] [Related]
8. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
[TBL] [Abstract][Full Text] [Related]
9. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
[TBL] [Abstract][Full Text] [Related]
10. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
12. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Strain EC; Stoller K; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
Coe MA; Lofwall MR; Vessels V; Nuzzo PA; Walsh SL
Psychopharmacology (Berl); 2021 Jul; 238(7):1857-1866. PubMed ID: 33988725
[TBL] [Abstract][Full Text] [Related]
14. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
Jones JD; Manubay JM; Mogali S; Metz VE; Madera G; Martinez S; Mumtaz M; Comer SD
Drug Alcohol Depend; 2017 Oct; 179():362-369. PubMed ID: 28844013
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.
Duke AN; Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2010 Aug; 211(3):303-12. PubMed ID: 20577717
[TBL] [Abstract][Full Text] [Related]
17. Abuse liability and reinforcing efficacy of oral tramadol in humans.
Babalonis S; Lofwall MR; Nuzzo PA; Siegel AJ; Walsh SL
Drug Alcohol Depend; 2013 Apr; 129(1-2):116-24. PubMed ID: 23098678
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
Mendelson J; Jones RT
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
[TBL] [Abstract][Full Text] [Related]
19. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.
Jones JD; Sullivan MA; Manubay J; Vosburg SK; Comer SD
Neuropsychopharmacology; 2011 Jan; 36(2):411-22. PubMed ID: 20980992
[TBL] [Abstract][Full Text] [Related]
20. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
